Placeholder

CNS: A Complex Therapeutic and Patient-Recruitment Market

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 157. Category: .

Product Description

An explosion of new science is leading to potential compounds to treat CNS diseases. The challenge for pharmaceutical companies and their partners is recruiting and retaining patients for trials.
Understanding the brain and how it functions has been one of the great, unanswered questions in medical history.
As the healthcare community closes in on unraveling the mystery of the brain, conditions are being studied in more detail and solutions for these conditions are being aggressively sought. The biggest problem, however, is that central nervous system (CNS) diseases and conditions are so wide-ranging in their types, symptoms, and outcomes that the breadth of research in this area may equal that of the rest of the body. Equally problematic is recruiting for clinical trials to support this research…

Sidebars:
A Global CNS Market Analysis
Selected Therapeutic Growth Areas, 2002 to 2003
Television: A Patient-Recruitment Tactic for a Postherpetic Neuralgia Trial
Sound Bites from the Field

Experts on this Topic
Scott H. Connor.
Director of Marketing, Acurian Inc., Horsham, Pa.; Acurian is a full-service provider of site and patient-recruitment solutions. For more information, visit acurian.com.
Donald J. Greene. VP of Sales and Marketing, Veritas Medicine Inc., Cambridge, Mass.; Veritas Medicine is a provider of clinical-trial assessment and recruitment services. For more information, visit veritasmedicine.com.
Deborah Kniuksta. Assistant Director, Patient Recruitment, Kendle, Cincinnati; Kendle is a global CRO delivering innovative and robust clinical-development solutions to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. For more information, visit kendle.com.
Jim Kremidas. Global Enrollment Optimization, Eli Lilly & Co., Indianapolis; Lilly is developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that help people live longer, healthier, and more active lives. For more information, visit lilly.com.
Harry Mansbach, M.D. Chief Medical Officer and VP, Clinical Development, Cortex Pharmaceuticals Inc., Irvine, Calif.; Cortex is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. For more information, visit cortexpharm.com.
Elizabeth Moench. President and CEO, MediciGroup, King of Prussia, Pa.; MediciGroup, founded in 1993, builds long-term client relationships by providing direct-to-patient clinical-trial recruitment and retention programs. For more information, visit medicigroup.com.
Christopher O’Brien, M.D. Chief Medical Officer, Prestwick Pharmaceuticals Inc., Washington, D.C.; Prestwick Pharmaceuticals is a product-based specialty pharmaceutical company engaged in the development and marketing of drugs for CNS diseases.For more information, visit prestwickpharma.com.
Tom Sturgis. President, Integrated Clinical Trial Services, Cary, N.C.; Integrated Clinical Trial Services is a full-service patient enrollment firm that provides clinical-trial sponsors, contract research organizations, and site networks with a comprehensive resource for patient-recruitment expertise. For more information, visit integratedtrials.com.

FEEDBACK